Replies to post #85693 on Amarin Corp Plc (AMRN)

[FlyFishingStocks]

F, I agree. One way or another, management has a strategic surprise for them.

[Biobillionair]

Flounder,
I think the chance of R-I being stop at interim is greater than 95%. I think both JL and HD's 70-ish% estimates prior to mid-June where correct, but new evidence is out suggesting treating adults >60 years or older with statins, (to drive LDL low) may actually cause harm.

http://www.telegraph.co.uk/science/2016/06/12/high-cholesterol-does-not-cause-heart-disease-new-research-finds/

This would be a huge change in treatment and Vascepa stands to benefit the most of all other treatments. Demand will be so high, supply will be an issue further driving the cost of the product.

V will actually be priced like liquid gold, and payers will line-up because it saves them health care costs.

JMHO,
BB

It also appears that Vascepa significantly lowers all known surrogate risk markers for Cardiovascular disease. This process slowly accelerates over years...likely due to cells being repaired from the prior poor AA:EPA ratios.